Toni Choueiri | BiotechTV

top of page

Dana-Farber Cancer Institute investigators describe a personalized cancer vaccine trial in kidney cancer that was published in Nature. All nine patients did not see their cancer recur.

Toni Choueiri and Patrick Ott describe how this peptide-based vaccine was peronalized to dozens of the patient's neoantigens in this this ad

Bright Minds

Feb 6

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

Dana-Farber Cancer Institute investigators describe a personalized cancer vaccine trial in kidney cancer that was published in Nature. All nine patients did not see their cancer recur.

Follow BiotechTV

Sponsors

Sponsor Spotlight